Abstract
Amikacin was used in 77 treatment courses at a dosage of ≥7.5 mg/kg every 8 h, and patients were monitored for ototoxicity by following serial audiograms, serum creatinine, and amikacin blood levels. Patients were leukopenic (58), were infected by gentamicin-resistant organisms (11), or had cystic fibrosis (8). Three patients developed tinnitus, but none had vertigo or nystagmus. Of 55 courses with pre- and post-treatment audiogram, 13 (24%) were associated with development of high-frequency hearing loss, which was usually bilateral. No patient had conversational hearing loss, and audiograms reverted to normal in three patients. Onset of cochlear damage occurred in one patient after therapy was stopped. The group with high-tone hearing loss, in comparison to the group without audiographic changes, received a larger mean total dose (24 versus 9.6 g), were treated for a longer duration (19 versus 9 days), and more frequently had previous aminoglycosides. Fifty-seven percent of patients with a “peak” serum level exceeding 32 μg/ml and 55% of patients with “trough” levels exceeding 10 μg/ml developed cochlear damage. There was no difference between the groups in age, body weight, previous cochlear damage, renal disease before or during therapy, or average daily dose. Both monitoring of blood levels and limiting duration of therapy may prevent amikacin ototoxicity.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodey G. P., Stewart D. In vitro studies of BB-K8, a new aminoglycoside antibiotic. Antimicrob Agents Chemother. 1973 Aug;4(2):186–192. doi: 10.1128/aac.4.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodey G. P., Valdivieso M., Feld R., Rodriguez V. Pharmacology of amikacin in humans. Antimicrob Agents Chemother. 1974 May;5(5):508–512. doi: 10.1128/aac.5.5.508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cabana B. E., Taggart J. G. Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans. Antimicrob Agents Chemother. 1973 Apr;3(4):478–483. doi: 10.1128/aac.3.4.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FROST J. O., HAWKINS J. E., Jr, DALY J. F. Kanamycin. II. Ototoxicity. Am Rev Respir Dis. 1960 Jul;82:23–30. doi: 10.1164/arrd.1960.82.1.23. [DOI] [PubMed] [Google Scholar]
- Finegold S. M. Toxicity of kanamycin in adults. Ann N Y Acad Sci. 1966 Jun 14;132(2):942–956. doi: 10.1111/j.1749-6632.1966.tb43018.x. [DOI] [PubMed] [Google Scholar]
- Meyer R. D., Lewis R. P., Carmalt E. D., Finegold S. M. Amikacin therapy for serious gram-negative bacillary infections. Ann Intern Med. 1975 Dec;83(6):790–800. doi: 10.7326/0003-4819-83-6-790. [DOI] [PubMed] [Google Scholar]
- Price K. E., Chisholm D. R., Misiek M., Leitner F., Tsai Y. H. Microbiological evaluation of BB-K 8, a new semisynthetic aminoglycoside. J Antibiot (Tokyo) 1972 Dec;25(12):709–731. doi: 10.7164/antibiotics.25.709. [DOI] [PubMed] [Google Scholar]
- Reiffenstein J. C., Holmes S. W., Hottendorf G. H., Bierwagen M. E. Ototoxicity studies with BB-K8, a new semisynthetic aminoglycoside antibiotic. J Antibiot (Tokyo) 1973 Feb;26(2):94–100. doi: 10.7164/antibiotics.26.94. [DOI] [PubMed] [Google Scholar]
- Stevens P., Young L. S., Hewitt W. L. Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med. 1975 Aug;86(2):349–359. [PubMed] [Google Scholar]
- Young L. S., Hewitt W. L. Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother. 1973 Dec;4(6):617–625. doi: 10.1128/aac.4.6.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yu P. K., Washington J. A., 2nd Comparative in vitro activity of three aminoglycosidic antibiotics: BB-K8, kanamycin, and gentamicin. Antimicrob Agents Chemother. 1973 Aug;4(2):133–139. doi: 10.1128/aac.4.2.133. [DOI] [PMC free article] [PubMed] [Google Scholar]